The use of β-blockers (BB) in heart failure (HF) has been considered a contradiction for
many years. Considering HF simply as a state of inadequate systolic function, BB were …

… to the role of β-blockers in heart failure therapy. Despite its limitations and negative mortality
results, the MDC trial sparked renewed interest in β-blockers as a therapy for heart failure. …

… highest in patients without beta blocker treatment irrespective of underlying HR. Our data,
therefore, support the use of beta blockers in all CHF patients. While outcomes in patients with …

… the benefit of beta-blocker therapy in heart failure in terms of reduction of mortality and
morbidity and to a similar extent within the studied range of severity of heart failure except for …

… betablocker therapy improves left ventricular function and reduces the rate of hospitalization
in patients with congestive heart failure. … reliably the effects of treatment on mortality. In these …

… –risk analysis involving beta-blockers in typical older heart failure patients irrespective of …
beta-blocker therapy, which at present is better documented than other heart failure therapies …

… be more difficult with β-blocker therapy because of the decreased heart rate. The symptom
data with β-blockers in heart failure are similar to exercise data … Beta blockers in heart failure …

… The purpose of this study was to determine the effect of beta-blocker therapy on outcomes
of hospitalized heart failure (HF) patients enrolled in the Evaluation Study of Congestive …

… with chronic heart failure. They should also identify appropriate patients and initiate therapy
in a … for the use of beta blocker therapy in patients with chronic heart failure and discusses its …

… quantify the impact of b-blocker therapy on QoL in CHF patients receiving optimal standard
… of b-blocker therapy on QoL in CHF patients receiving optimal standard therapy. Standard …